US/UK/Canada

Share

Contacts

  • Pål Ryfors

    CEO


    Karlavägen 60, 114 49 Stockholm
    0709623669
    http://www.episurf.com
    • Pick a time period -
    Tags ( Active)

    Interim Report 1 January - 30 September 2024

    · Improvement of financial result through lower cost base and increased revenues · Focus towards expansion of US sales force · Continued progress of 510(k)-process for great toe implant “I am pleased to present a quarterly report in which we seriously demonstrate that our measures positively impact the income statement. In the third quarter, we improved our result by SEK 4.9m compared to the corresponding quarter last year, and we now see that our cost-saving initiatives are yielding results. With increased revenues, we have good opportunities to continue to step into the

    Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2025

    In accordance with the decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee. The members of the Nomination Committee shall agree on a chairman/woman of the committee. In accordance with the above principles, the Nomination Committee consists of the following four members: · Ulf Grunander, Chairman of the Board Episurf Medical

    Niles Noblitt, through Sacajo Investments LLC, makes investment in Episurf through an arrangement with CEO Pål Ryfors

    In order to facilitate settlement of an acquisition of 9,526,170 Class B shares in Episurf Medical AB (publ) (“Episurf” or the “Company”) by Sacajo Investments LLC (“Sacajo”), a trust with the Company’s Senior Advisor Niles Noblitt as first member, Sacajo and Pål Ryfors, CEO of Episurf, have agreed that Pål Ryfors shall hold the shares during an interim period. Consequently, Pål Ryfors will acquire 9,526,170 Class B shares in Episurf from Sacajo for a purchase price of SEK 2,286,280.80, corresponding to SEK 0.24 per share. Payment for the shares is made by Pål Ryfors issuing a promissory

    Episurf Medical: Update on 510(k) application for big toe implant

    Episurf Medical (Nasdaq: EPIS B) today provides an update on the company's 510(k) application to the US FDA, for market clearance of the company's implant for treatment of osteoarthritis in the so-called 1st MTP joint in the big toe. During this process, the company has exchanged information with the FDA, and this process will continue shortly. "We are pleased to have come this far in the process. We have in-depth experience of interacting with the FDA, and we know that it is difficult to forecast these processes accurately, but we certainly feel that we are moving forward. We will not

    Episurf Medical to present at Pareto Securities Healthcare Conference on September 19, 2024

    Episurf Medical (Nasdaq: EPIS B) to present at Pareto Securities Healthcare Conference on September 19, 2024. The event is arranged by Pareto and the company will be represented by its CEO Pål Ryfors. Time: 11:05-11:25 CESTFormat: 20 minutes including Q&ALocation: Studio 8, Downtown Camper, Drottninggatan 28, 111 51 Stockholm The presentation slides will be made available afterwards on our website www.episurf.com.

    Episealer® technology to be presented at international scientific congress

    Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® technology will be presented at the 7th ICRS (International Cartilage Regeneration & Joint Preservation Society) Summit in Catania, Italy, on September 25-27, 2024. The Episealer® technology will be presented at two sessions as part of the scientific program. Dr. Gary Levengood of Sports Medicine South, part of the Northside Health System, GA, USA, has been invited to present his experience using the Episealer® Patellofemoral System, introduced on the US market in 2023. This is the first time usage of the Episealer®

    Interim Report 1 January – 30 June 2024

    · 45% sales growth despite transformation of sales organization · Additional SEK 12m in annual cost savings identified · Pause of EPIC-Knee trial to the advantage of other initiatives“We have started considerably faster in the US than what we have seen in any other market. For example, during the second quarter, the US market represents approx. 45% of the turnover in Germany, which is by far our largest market to date. In other words, we follow our strategy. We also see good opportunities to continue the beaten track at an ever-increasing speed. We will continue with our commercial

    Change in number of shares and votes in Episurf Medical

    Episurf Medical AB (NASDAQ: EPIS B) has, pursuant to previously announced information, carried out a rights issue of units consisting of shares of series B and warrants of series TO13 B. The rights issue has resulted in a change in the number of shares and votes in the company. Through the rights issue, the number of shares has increased by 375,662,430 shares of series B and the number of votes has increased by 375,662,430. Furthermore, the company has, pursuant to previously announced information, carried out a set-off issue of units consisting of shares of series B and warrants of

    Episurf Medical resolves on an issue of units to guarantors in connection with the completed rights issue

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT

    Episurf Medical announces outcome of the rights issue

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT

    Episurf Medical publishes prospectus in connection with the company’s partially guaranteed rights issue of up to approximately SEK 120 million

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT

    Summary from the Extraordinary General Meeting of Episurf Medical (publ)

    Episurf Medical AB (publ) held an Extraordinary General Meeting in Stockholm today 22 May 2024 at which it was resolved, among other things, to approve the Board of Directors’ resolution on a rights issue of units.The Extraordinary General Meeting resolved, in accordance with the Board of Directors’ proposal, to approve the Board of Directors’ resolution of 22 April 2024 to issue units consisting of shares of series B and warrants of series TO13 B with preferential rights for existing shareholders (the “Rights Issue”). In order to enable the execution of the Rights Issue, the

    Interim Report 1 January – 31 March 2024

    • Reduced cost base following implementation of restructuring programme• Ongoing regulatory process targeting 510(k)-clearance Episealer® MTP-System• Largest distribution agreement to date in the US with Performance Orthopaedics of the Carolinas, Inc., an exclusive distributor for DePuy Synthes Reconstruction products for North Carolina and South Carolina“During the first quarter, our transition towards a higher degree of distributor sales continued. Of course, this change has affected our sales negatively in the short term, but it is the right step to take to reach out on a broader

    Notice of Extraordinary General Meeting of Episurf Medical AB (publ)

    The shareholders of Episurf Medical AB (publ), reg. no. 556767-0541 (“Episurf” or the “Company”), are hereby summoned to the Extraordinary General Meeting on 22 May 2024, at 09:30 at the Company’s office on Karlavägen 60, SE-114 49 Stockholm, Sweden. Entry and registration opens at 09:00. The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) and the Company’s Articles of Association, decided that the shareholders shall be able to exercise their voting rights by postal voting prior to the General Meeting. Accordingly,

    Episurf Medical announces a partially secured rights issue of units of up to approximately SEK 120 million

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT

    Summary from Annual General Meeting of Episurf Medical AB (publ)

    Episurf Medical AB (publ) (“Episurf” or the “Company”) held its Annual General Meeting (the “Meeting”) on Tuesday, 9 April 2024 in Stockholm.The income statements and the balance sheets for the Company and the group were approved and the Board of Directors and the CEO were discharged from liability for the financial year 2023. The Meeting resolved, in accordance with the proposal of the Board of Directors, that the Company shall not pay dividends for the financial year 2023. The Meeting resolved to approve the remuneration report for the financial year 2023. In accordance with the

    Episurf Medical AB’s 2023 annual report is now available

    Episurf Medical’s annual report for 2023 is available as of today at the company’s website, www.episurf.com.  Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB, Karlavägen 60, 114 49 Stockholm, Sweden or by email: ir@episurf.com.

    Episurf Medical to present at Life Sciencedagen on March 6, 2024

    Episurf Medical (Nasdaq: EPIS B) will attend Life Sciencedagen which is held on March 6, 2024. The company will be represented by its CEO Pål Ryfors. The presentation will be streamed live at 14:45 CET at www.lifesciencedagen.se  and will also be made available afterwards on our website www.episurf.com. The event takes place at Wallenberg Conference Center, Sahlgrenska Academy, at Medicinareberget in Gothenburg.

    Notice of Annual General Meeting of Episurf Medical AB (publ)

    This English translation of the notice is an unofficial translation of the Swedish original. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders in Episurf Medical AB (publ), 556767-0541 (“Episurf” or the “Company”), are hereby summoned to the Annual General Meeting (the “Meeting”) on Tuesday, 9 April 2024, at 15:00 (CEST) at the Company’s office at Karlavägen 60, SE-114 49 Stockholm, Sweden. Entry and registration begin at 14:30 (CEST). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the

    Nomination Committee’s proposal regarding board of directors of Episurf Medical AB for 2024

    Episurf Medical’s Nomination Committee proposes six regular board members without deputies, including the re-election of Ulf Grunander as chairman of the board and the proposed new election of Dr. Jess Lonner as board member, to be confirmed at the annual general meeting. Other board members are proposed for re-election. Ulf Grunander was elected chairman in 2023 and has been a board member since 2021. Other board members proposed for re-election are Board Members Leif Ryd (member since 2009), Christian Krüeger (member since 2016), Laura Shunk (member since 2017) and Annette Brodin Rampe (

    Year-end Report 1 January – 31 December 2023

    · Continued stable growth despite restructuring of commercial organization, and satisfactory start in the US with significant opportunities ahead · Restructuring program completed with planned cost reduction expected 2024 · 510(k)-process ongoing with US FDA for big toe implant“Despite significantly restructuring our sales force, we ended the year with another record quarter. On average, we have grown our gross order intake by more than 50% during the last five quarters. During 2023, the gross order intake reached SEK 11.1m (+56%). The usage of our technology increased globally and

    Results from up to 10 years follow-up of Episealer® patients accepted for presentation at international orthopaedic congress

    Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Survivorship and clinical outcome of a novel personalized metal implant for the treatment of cartilage lesions of the knee”, by Dr.ssa Francesca de Caro has been accepted for a podium presentation at The Partial Knee Meeting 2024. The congress will take place in Antwerp, Belgium, on January 25-26, 2024. The abstract reports on high implant survival rate and good clinical outcome for 22 patients who were treated with Episurf Medical’s personalised implant Episealer® Knee as treatment for chondral and osteochondral defects

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media